度-QTcF模拟Icenticaftor从一个随机,安慰剂和积极控制的健康参与者的全面QT研究
Ganesh R Iyer1, Borje Darpo2, Hongqi Xue2
1Biomedical Research, Novartis Pharmaceuticals Corporation, Cambridge, MA, USA.
Clinical pharmacology in drug development
|January 29, 2024
概括
作为囊性纤维化转膜受体增强剂的Icenticaftor在健康参与者中显示了QTcF间隔的轻微,临床上无意义的缩短. 这项研究评估了其心脏安全性,在治疗剂量或超治疗剂量时没有发现任何影响.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 心血管安全药理学 心血管安全药理学
- 药物开发 药物开发
背景情况:
- 伊森蒂卡夫托 (QBW251) 是囊性纤维化转膜受体的增强剂.
- 目前正在研究其在慢性阻塞性肺病 (COPD) 中的潜在益处,通过改善膜清除.
- 在治疗使用之前,评估心脏安全性,特别是对QT间隔的影响至关重要.
研究的目的:
- 为了评估治疗和超治疗剂量伊森蒂卡弗托对心电图 (ECG) 参数的影响.
- 在健康参与者中评估icenticaftor的度-QTc关系.
- 为了确定icenticaftor延长QT间隔的潜力,这是心脏风险的标志物.
主要方法:
- 在46名健康志愿者中进行了安慰剂和积极控制的四路交叉彻底的QT研究.
- 参与者接受了口服伊森蒂卡夫托尔300毫克每天两次 (治疗) 和750毫克每天两次 (超级治疗) 6天.
- 莫西弗洛克萨辛作为阳性对照;分析了心电图参数,包括弗里德里西亚校正的QT (QTcF) 间隔.
主要成果:
- 在治疗剂量和超治疗剂量下,Icenticaftor在QTcF间隔上表现出轻微的缩短作用.
- 度-QTc分析显示了浅,略微负的斜率,表明没有显著的QT延长风险.
- 在观察到的度范围 (高达9540 ng/mL) 中,超过10毫秒的QTcF影响被排除在外.
结论:
- 在研究的剂量中,icenticaftor显示QTcF间隔的轻微缩短.
- 这种效应不太可能具有临床意义,这表明心脏安全性概况有利.
- 该研究证实了moxifloxacin的测定灵敏度,并提供了关于icenticaftor度与QTc关系的可靠数据.
关键词:
在 QT 间隔的长度.在QTc中,QTc是QTc.QTcF 的时间.健康的个人健康的个人一个icenticaftor或一个QBW2511.药理动力学是药理动力学的一个方面.药物动力学 药物动力学再极化再极化是什么意思进行全面的QT研究.更多相关视频
07:04Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
19.3K
11:15Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
4.6K
相关概念视频
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Drug Concentration Versus Time Correlation
775
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
775
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
One-Compartment Model: IV Infusion
198
Intravenous (IV) infusion is often utilized when continuous and controlled drug delivery is necessary, such as during surgery or in the treatment of chronic diseases. This method offers numerous advantages, including immediate drug action, precise control over dosage, and bypassing the first-pass metabolism.
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
198
Compartment Models: Two-Compartment Model
5.5K
The two-compartment model divides the body into central and peripheral compartments to account for varying blood perfusion rates among organs and tissues, affecting drug distribution. The central compartment includes blood and highly perfused tissues with rapid drug distribution, while the peripheral compartment contains tissues with slower drug distribution. After a single IV bolus dose, the drug concentration is high in plasma and low in tissues. The drug distribution between compartments...
5.5K
